PALO ALTO, Calif., May 28, 2014 /PRNewswire/ -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that CEO Jeffrey K. Tong, Ph.D., is scheduled to participate in the following conferences in June:
- Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 10:00 a.m. EDT in New York City, NY.
- Boston CEO Conference on Wednesday, June 4, 2014 at 11:15 a.m. EDT in Boston, MA.
About Nora Therapeutics, Inc.
Nora Therapeutics is a privately-held biotechnology company focused on developing therapeutics to address IVF failure and recurrent pregnancy loss, two reproductive conditions with significant unmet need. Nora's lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information, please visit our website at www.noratherapeutics.com.
SOURCE Nora Therapeutics